Navigation Links
CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price
Date:8/26/2008

WOBURN, Mass., Aug. 26 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi) announces the release of the Maestro(TM) EX In Vivo Imaging System. The new system incorporates CRi's state-of-the-art FLEX technology and becomes the entry-level instrument of choice for in vivo fluorescence imaging.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080826/NETU054 )

FLEX technology represents a significant advancement of CRi's unique solid-state tunable optics that for the first time enables both broad- and narrow-band spectral imaging at the click of a button. The user can select high optical throughput for reduced experiment times or increased spectral resolution for enhanced separation of similar fluorescent labels.

Accurate spectral detection is essential for quantitative signal unmixing. Patent-pending Maestro software tools complement the improved optical capabilities of the Maestro EX by ensuring accurate and automated characterization of fluorescent signals in spectrally complex samples. Dynamic Contrast Enhancement (DyCE(TM)) is available as an accessory. DyCE is a revolutionary all-optical anatomic imaging solution for mice that also helps eliminate signals from non-specific binding in much less time than conventional means-by as much as 90% less time.

"You will be able to detect and measure more markers in your mouse model and resolve even extremely closely spaced and overlapping emission signals." explains James Mansfield, Director of Multispectral Imaging Systems at CRi.

The Maestro EX enables more precise detection and quantitation of molecular probes in live animals and complements the automated high-throughput Maestro 2 imaging system, by providing comparable imaging performance in a design intended for lower-throughput manual operation.

By providing unprecedented accuracy, sensitivity, and flexibility, along with powerful and intuitive software, the Maestro EX solidifies CRi's reputation as the industry's leading provider of in vivo fluorescence imaging systems.

Cambridge Research & Instrumentation, Inc (CRi) is a Boston-based biomedical imaging company providing innovative optical imaging solutions for more than 20 years. CRi's multidisciplinary team is dedicated to providing comprehensive solutions that enable our customers to produce breakthroughs in research and medical care. CRi technology helps extract new disease-specific information from biological and clinical samples in the physiological, morphological, and biochemical context of intact tissues and organisms.

With over 80 patents pending and issued, CRi's award-winning innovations are being utilized around the world in a wide range of settings, ranging from academic researcher to pharmaceutical drug development to clinical medicine. CRi is headquartered in Woburn, Massachusetts, and operates a state-of-the-art manufacturing facility. We are able to rapidly design and manufacture system- level solutions for a variety of growing market applications.

Visit http://www.cri-inc.com/maestro-pr to find out more about the Maestro EX system.

For more information visit our website at http://www.cri-inc.com or contact:

Ross Nakatsuji

CRi Marketing/Sales Group Leader

35-B Cabot Road, Woburn, MA 01801 USA

(P) 1-781-935-9099, extension 177, (C) 1-781-405-4000,

(E) rnakatsuji@cri-inc.com


'/>"/>
SOURCE Cambridge Research & Instrumentation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):